BC Week In Review | Nov 10, 2014
Clinical News

ARA 290 regulatory update

FDA granted Fast Track designation to Araim's ARA 290 to treat sarcoidosis-associated small fiber neuropathy. The short tissue protective peptide is in Phase IIb testing for the indication, with Phase III testing slated for 4Q15....
BC Week In Review | Oct 28, 2013
Clinical News

ARA 290 regulatory update

The European Commission granted Orphan Drug designation to Araim's ARA 290 to treat sarcoidosis. The short tissue protective peptide is in Phase IIb testing for small fiber neuropathy in sarcoidosis patients and Phase IIa testing...
BC Innovations | Feb 21, 2013
Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Burns Erythropoietin (EPO); colony stimulating factor 2 receptor-b low-affinity (CSF2RB; CD131) Mouse studies suggest an EPO mimetic could help treat burns....
Items per page:
1 - 3 of 3